Keytruda: A Leading Driver Behind The Rising Prevalence Of Cancer Driving Growth In The Keytruda Market Market Expansion in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Keytruda Industry Market Size Be by 2025?
The Keytruda market has witnessed a significant expansion in its size over the past few years. It is projected to escalate from $21.6 billion in 2024 to $23.8 billion in 2025, marking a compound annual growth rate (CAGR) of 10.2%. Factors contributing to this growth during the historic period include enhanced patient results, wide-ranging acceptance of immunotherapy, advancements in research and development, better patient adherence, and a surge in the adoption of Keytruda.

What's the Long-Term Growth Forecast for the Keytruda Market Size Through 2029?
Expectations for the Keytruda market size forecasts a robust expansion in the coming years. The market is projected to reach a value of $34.61 billion in the year 2029, growing with a CAGR of 9.8%. The anticipated growth during the forecasted period is accredited to the expansion of indications, the advent of new markets, increased cancer prevalence, a surge in healthcare spending, and the rising demand for precision medicine. Several trends could be seen during this forecast period, including the increased demand for targeted therapies, progress in immunotherapy and diagnostic technologies, increased need for cancer treatment, and advancements in cancer-related research.

View the full report here:
https://www.thebusinessresearchcompany.com/report/keytruda-global-market-report

What Are the Key Growth Drivers Fueling the Keytruda Market Expansion?
The keytruda market is being bolstered by the escalating incidence of cancer. Cancer, typified by erratic cell growth and propagation, is a multifaceted cluster of diseases. Its spread is attributed to genetic components, lifestyle choices, environmental influences, and hormonal aspects. Keytruda (pembrolizumab) enhances cancer management by empowering the body's immune system to combat cancer cells more efficiently. It epitomizes a significant development in cancer management, leveraging the capabilities of the immune system to focus on and eliminate cancer cells, offering renewed optimism for many individuals with late-stage or metastasized cancers. For instance, data from the American Cancer Society, a US nonprofit committed to cancer advocacy, indicated an increase in cancer cases to 2,001,140 in January 2024, from 1,958,310 in 2023, recording a growth of 2.19%. Hence, the escalating incidence of cancer fuels the growth of the keytruda market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16457&type=smp

What Are the Key Trends Driving Keytruda Market Growth?
Leading firms in the Keytruda market such as Merck are launching novel products like pembrolizumab to broaden the range of treatment solutions. Pembrolizumab is a monoclonal antibody medicine, part of the immune checkpoint inhibitors drug category. Marketed under Keytruda brand, it targets and obstructs the function of a protein known as PD-1 (programmed cell death protein 1) on T immune cells. For example, in November 2023, Merck, a renowned US-based Keytruda manufacturer, introduced KEYTRUDA (pembrolizumab) used in concurrence with fluoropyrimidine- and platinum-inclusive chemotherapy, sanctioned by the US-based government entity, the Food and Drug Administration. This combination showcases remarkable improvements in terms of overall duration of survival and period of disease stability, compared to sole chemotherapy, thus depicting a significant development in gastric cancer treatment. In various clinical trials, this amalgamated therapy depicted advancements in overall survival (OS), period of disease stability (PFS), and the overall response rate (ORR) compared to using chemotherapy independently.

How Is the Keytruda Market Segmented?
The keytruda market covered in this report is segmented -

1) By Cancer Type: Melanoma, Lung Cancer, Head And Neck Cancer, Hodgkin Lymphoma, Stomach Cancer, Urothelial Carcinoma
2) By Payer Type: Commercial, Medicare, Medicaid
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:
1) By Melanoma: Advanced Or Unresectable Melanoma, Adjuvant Treatment For Melanoma
2) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
3) By Head And Neck Cancer: Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Recurrent Or Metastatic Head And Neck Cancer
4) By Hodgkin Lymphoma: Classical Hodgkin Lymphoma, Relapsed Or Refractory Hodgkin Lymphoma
5) By Stomach Cancer: Advanced Or Metastatic Gastric Cancer, Esophagogastric Junction Cancer
6) By Urothelial Carcinoma: Advanced Or Metastatic Urothelial Carcinoma, Muscle-Invasive Bladder Cancer

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=16457&type=smp

Which Companies Are Leading the Charge in Keytruda Market Innovation?
Major companies operating in the keytruda market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Chugai Pharmaceutical Co. Ltd., BioNTech AG, Organon Co., Ono Pharmaceutical Co. Ltd., Samsung Bioepis Co. Ltd., Fate Therapeutics Inc., Merck Sharp & Dohme Corp., KinBio, Schering-Plough AB, LGM Pharma LLC, Gritstone Bio Inc.

Which Regions Are Leading the Global Keytruda Market in Revenue?
North America was the largest region in the keytruda market in 2023. The regions covered in the keytruda market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16457

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.